Assessment of HER2 status in breast cancer;Actualité des tests HER2 dans le cancer du sein

Bulletin du Cancer

Volumn 91, Issue SPEC. ISS. DEC., 2004, Pages

  Penault Llorca, Frédérique ^a   Cayre, Anne ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

Breast cancer; HER2; Immunohistochemistry; In situ hybridization; Quality assurance

Indexed keywords

TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; PROTO ONCOGENE; QUALITY CONTROL; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2;

EID: 12244268694     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Piccart M, Dochy E, Cardoso F. Nouveautés dans le traitement médical du cancer du sein. Bull Cancer 2003; 90: 46-52.
2. Diaz NM. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Cancer control 2001; 8: 415-8.
3. Hannah W, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A. Defining a test for HER2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 2001; 14: 677-85.
4. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J Pathol 2003; 199: 411-7 [Comment on 418-23].
5. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of Herceptest™ in determining HER/neu status of breast cancers using FDA-approved scoring system. J Clin Oncol 1999; 17: 1983-7.
6. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-64.
7. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001; 19: 354-63.
8. Tubbs RR, Stoler M. The quality of Her-2/neu predicive immunohistochemistry: something FISHy? Mod Pathol 2000; 13: 1-3.
9. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001; 7: 1669-75.
10. Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003; 199: 418-23.
11. Penault-Llorca F, Balaton A, Sabourin JC, Le Doussal V. Evaluation immunohistochimique du statut HER2 dans les carcinomes mammaires infiltrants: mise au point du protocole technique et de la lecture des résultats: Recommandations. Ann Pathol 2002; 22: 150-7.
12. Fiche M. Hybridation in situ avec sonde fluorescente: développements actuels et perspectives en pathologie. Ann Pathol 2001; 21: 383-5.
13. Di Leo A, Dowsett M, Horten B, Penault-Llorca F. Current status of HER2 testing. Oncology 2002; 63 (suppl 1): 25-32.
14. Vincent-Salomon A, Mac Grogan G, Couturier J, Arnould L, Denoux Y, Fiche M, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the french multicentric GEFPICS study. Histopathology 2003; 42: 337-47.
15. Ginestier C, Charafe-Jauffret E, Penault-Llorca F, Geneix J, Adelaide J, Chaffanet M, et al. Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol 2004; 202: 286-98.
16. Zarbo RJ, Hammond ME. Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med 2003; 127: 549-53.
17. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004; 101: 9393-8.
18. Jacobs TW, Mc Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Her-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol 2000; 113: 251-8.
19. Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 2000; 13: 1238-43.
20. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20: 3095-105.
21. Van de Vijver M. Emerging technologies for HER2 testing. Oncology 2002; 63 (Suppl 1): 25-32.
22. Arnould L, Denoux Y, Macgrogan G, Penault-Llorca F, Fiche M, Treilleux I, et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003; 88: 1587-91.
23. Denoux Y, Arnould L, Fiche M, Lannes B, Couturier J, Vincent-Salomon A, et al. Recherche de l'amplification de HER2.1a CISH est-elle une alternative à la technique FISH? Ann Pathol 2003; 23: 617-22.
24. Nunes RA, Harris LN. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 2002; 3: 125-35; [discussion 136-137].
25. Leyland-Jones B, Marty M, Baselga J, Gatzemeir U, Barton C, Lennon S. Effect of trastuzumab and chemotherapy on circulating HER2 extracellular domain in patients with metastatic breast cancer and non small lung cancer. J Clin Oncol 2004; 22: 145-570.
26. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003; 16: 173-82.
27. Cell markers and cytologenetics committees, college of American Pathologists. Clinical Laboratory Assays for Her2/neu amplification and overexpression. Arch Pathol Lab Med 2002; 126: 803-8.
28. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 2002; 118: 408-17.
29. Paik S, Bryant J, Tan-Chiu E, Romond E, Miller W, Park K, et al. Real-world performance of HER2 resting: National Surgical Adjuvant Breast and Bowel Project Experience. J Natl Cancer Inst 2002; 94: 852-4.
30. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst 2002; 94: 855-7.
31. Jacquemier J, Ginestier C, Bertucci F, Jauffret EC, Geneix J, Birnbaum D. Le « tissue microarrays »: nouvel outil de transfert et de contrôle de qualité en cancérologie. Bull Cancer 2003; 90: 31-8.
32. Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, et al. Best practice n° 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004; 57: 233-7.
33. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
34. Campone M, Merlin JL, Fumoleau P. Place de l'association trastuzumab et taxanes dans la prise en charge thérapeutique des cancers du sein: de la préclinique aux applications cliniques. Bull Cancer 2003; 90: 614-22.